• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    11/21/24 4:51:50 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRS alert in real time by email
    SC 13G 1 ea0222156-13gvivo_aclaris.htm SCHEDULE 13G
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Aclaris Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.00001 par value

    (Title of Class of Securities)

     

    00461U105

    (CUSIP Number)

     

    November 19, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity Fund Holdings, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) þ

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    7,955,160 (1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    7,955,160 (1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,955,160 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.4% (2)

    12.

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) The number represents shares of common stock, $0.00001 par value (the “Common Stock”) of Aclaris Therapeutics, Inc. (the “Issuer”) held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    (2) Based on 106,986,497 shares of Common Stock outstanding following the closing of the Issuer’s private placement offerings, as disclosed in the Issuer’s current report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on November 18, 2024.

     

    2

     

     

    1.

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) þ

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    7,955,160 (1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    7,955,160 (1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,955,160 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.4% (2)

    12.

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    (2) Based on 106,986,497 shares of Common Stock outstanding following the closing of the Issuer’s private placement offerings, as disclosed in the Issuer’s current report on Form 8-K filed with the SEC on November 18, 2024.

     

    3

     

     

    1

    NAMES OF REPORTING PERSONS

     

    Vivo Asia Opportunity Fund Holdings, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) þ

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    5

    SOLE VOTING POWER

     

    933,728 (1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    933,728 (1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    933,728 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.9% (2)

    12

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) The number represents shares of Common Stock of the Issuer held of record by Vivo Asia Opportunity Fund Holdings, L.P.  Vivo Opportunity Cayman, LLC is the general partner of Vivo Asia Opportunity Fund Holdings, L.P.  

     

    (2) Based on 106,986,497 shares of Common Stock outstanding following the closing of the Issuer’s private placement offerings, as disclosed in the Issuer’s current report on Form 8-K filed with the SEC on November 18, 2024.

     

    4

     

     

    1

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity Cayman, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) þ

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    5

    SOLE VOTING POWER

     

    933,728 (1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    933,728 (1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    933,728 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.9% (2)

    12

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) The number represents shares of Common Stock of the Issuer held of record by Vivo Asia Opportunity Fund Holdings, L.P.  Vivo Opportunity Cayman, LLC is the general partner of Vivo Asia Opportunity Fund Holdings, L.P.  

     

    (2) Based on 106,986,497 shares of Common Stock outstanding following the closing of the Issuer’s private placement offerings, as disclosed in the Issuer’s current report on Form 8-K filed with the SEC on November 18, 2024.

     

    5

     

     

    Item 1. (a) Name of Issuer:

     

    Aclaris Therapeutics, Inc. (the “Issuer”)

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    701 Lee Road, Suite 103, Wayne, PA 19087

     

    Item 2. (a) Name of Person Filing:

     

    Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC

     

    Vivo Asia Opportunity Fund Holdings, L.P and its General Partner Vivo Opportunity Cayman, LLC

     

      (b) Address of Principal Business Office or, if None, Residence:

     

    192 Lytton Avenue, Palo Alto, CA 94301

     

      (c) Citizenship:

     

    Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership.

     

    Vivo Opportunity, LLC is a Delaware limited liability company.

     

    Vivo Asia Opportunity Fund Holdings, L.P. is a Cayman Islands limited partnership.

     

    Vivo Opportunity Cayman, LLC is a Cayman Islands limited liability company.

     

      (d) Title of Class of Securities:

     

    Common Stock, $0.00001 par value

     

      (e) CUSIP Number:

     

    00461U105

     

    Item 3. If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act.
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act.
           
      (c) ☐  Insurance company as defined in Section 3(a)(19) of the Act.
           
      (d) ☐  Investment company registered under Section 8 of the Investment Company Act of 1940.
           
      (e) ☐  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) ☐  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) ☐  A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);
           
      (h) ☐  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ☐  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ☐  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐  Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

     

    Not Applicable.

     

    6

     

     

    Item 4. Ownership.

     

      (a) Amount Beneficially Owned:

     

    Vivo Opportunity, LLC beneficially owns 7,955,160 shares of Common Stock. The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    Vivo Opportunity Cayman, LLC beneficially owns 933,728 shares of Common Stock. The securities are held of record by Vivo Asia Opportunity Fund Holdings, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Asia Opportunity Fund Holdings, L.P.

     

      (b) Percent of class:

     

    Vivo Opportunity Fund Holdings, L.P.: 7.4%

    Vivo Opportunity, LLC: 7.4%

    Vivo Asia Opportunity Fund Holdings, L.P.: 0.9%

    Vivo Opportunity Cayman, LLC.: 0.9%

     

      (c) Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote:  

    Vivo Opportunity Fund Holdings, L.P.: 7,955,160 shares

    Vivo Opportunity, LLC: 7,955,160 shares

    Vivo Asia Opportunity Fund Holdings, L.P.: 933,728 shares

    Vivo Opportunity Cayman, LLC: 933,728 shares

     

      (ii) Shared power to vote or to direct the vote: 0

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    Vivo Opportunity Fund Holdings, L.P.: 7,955,160 shares

    Vivo Opportunity, LLC: 7,955,160 shares

    Vivo Asia Opportunity Fund Holdings, L.P.: 933,728 shares

    Vivo Opportunity Cayman, LLC: 933,728 shares        

     

      (iv) Shared power to dispose of or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

     

    7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 21, 2024

     

    Vivo Opportunity Fund Holdings, L.P.

     

    By: Vivo Opportunity, LLC, its General Partner

     

    /s/ Kevin Dai  
    Name: Kevin Dai  
    Title: Managing Member  

     

    Vivo Opportunity, LLC

     

    /s/ Kevin Dai  
    Name: Kevin Dai  

    Title:

    Managing Member

     

     

    Vivo Asia Opportunity Fund Holdings, L.P.

     

    By: Vivo Opportunity Cayman, LLC, its General Partner

     

    /s/ Kevin Dai  
    Name: Kevin Dai  
    Title: Managing Member  

     

    Vivo Opportunity Cayman, LLC

     

    /s/ Kevin Dai  
    Name: Kevin Dai  
    Title: Managing Member  

     

    8

     

     

    EXHIBIT INDEX

     

    Exhibit

     

    99.1Joint Filing Statement

     

    9

     

    Get the next $ACRS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ACRS

    DatePrice TargetRatingAnalyst
    7/10/2025$6.00Overweight
    Piper Sandler
    5/28/2025$8.00Outperform
    Wedbush
    3/18/2025Overweight
    Cantor Fitzgerald
    12/23/2024$20.00Neutral → Buy
    H.C. Wainwright
    11/20/2024Neutral → Overweight
    Cantor Fitzgerald
    11/19/2024$2.00 → $7.00Market Perform → Outperform
    Leerink Partners
    11/19/2024$8.00Neutral → Buy
    BTIG Research
    11/19/2024$2.00 → $7.00Hold → Buy
    Jefferies
    More analyst ratings

    $ACRS
    SEC Filings

    See more
    • Aclaris Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

      6/30/25 6:59:26 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Aclaris Therapeutics Inc.

      S-8 - Aclaris Therapeutics, Inc. (0001557746) (Filer)

      6/5/25 5:01:02 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

      6/5/25 4:01:51 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

      WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2025 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, June 30, 2025. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000 Index, which remain

      6/30/25 9:31:48 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

      WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a corporate presentation during the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation will take place on Monday, June 30, 2025 at 11:30 AM EDT. A live and archived webcast of the presentation will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage b

      6/26/25 4:01:27 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

      - Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company's potential best-in-class investigational bispecific anti-TSLP/IL-4R antibody. The program will consist of a Phase 1a single and multiple ascending dose (SAD/MAD) portion in healthy volunteers, followed by an expected Phase 1b proof of conce

      6/23/25 6:59:36 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Aclaris Therapeutics with a new price target

      Piper Sandler resumed coverage of Aclaris Therapeutics with a rating of Overweight and set a new price target of $6.00

      7/10/25 8:47:17 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Aclaris Therapeutics with a new price target

      Wedbush initiated coverage of Aclaris Therapeutics with a rating of Outperform and set a new price target of $8.00

      5/28/25 8:54:54 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Aclaris Therapeutics

      Cantor Fitzgerald resumed coverage of Aclaris Therapeutics with a rating of Overweight

      3/18/25 8:23:58 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Milano Vincent converted options into 4,793 shares, increasing direct ownership by 38% to 17,316 units (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      6/9/25 4:20:29 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mehra Anand converted options into 4,793 shares, increasing direct ownership by 0.68% to 714,823 units (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      6/9/25 4:20:24 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schiff Andrew N converted options into 4,793 shares, increasing direct ownership by 52% to 13,960 units (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      6/9/25 4:20:31 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Leadership Updates

    Live Leadership Updates

    See more

    $ACRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

      WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer. Dr. Hall's extensive medical and clinical development experience in areas including immunology and antibody development will be essential as he leads Aclaris' clinical strategy to fully leverage the opportunities in the Company's portfolio of immuno-inflammatory product candidates. "At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and

      4/29/25 7:00:32 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

      CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.

      4/23/24 8:00:00 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Announces Key Leadership Transitions

      - Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board of Directors - Kevin Balthaser appointed Chief Financial Officer to succeed retiring Frank Ruffo - Matthew Rothman appointed General Counsel WAYNE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced several key leadership changes. Effective January 1, 2023, co-founder

      11/22/22 4:01:00 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mehra Anand bought $1,499,998 worth of shares (666,666 units at $2.25), increasing direct ownership by 1,537% to 710,030 units (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      11/20/24 4:20:04 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $472,757 worth of shares (373,569 units at $1.27) (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      8/5/24 3:57:34 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $359,010 worth of shares (273,730 units at $1.31) (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      7/31/24 4:10:09 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/25/24 11:02:19 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/22/24 4:00:23 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/21/24 4:51:50 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Financials

    Live finance-specific insights

    See more
    • Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial res

      5/8/25 6:50:51 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

      - Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ's Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Expected in the First Half of 2025 to Inform Internal Development Programs - - Initiation of Enrollment in Phase 2b Trial for Bosakitug in Atopic Dermatitis (AD) on Track for the First Half of 2025 - - Cash Runway Expected into 2028 - WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inf

      2/27/25 6:59:55 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

      - Enhances Aclaris' pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) --  Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-cl

      11/18/24 8:10:04 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care